IREN has turned the tables on its bears this week — up 25% to $59.78, with shorts sitting on a position that now looks decidedly uncomfortable.
The narrative shift here is stark. Three recent notes documented bears pressing aggressively into a falling stock. That picture has reversed. IREN gained 25.2% on the week and 5.2% on Tuesday alone, erasing much of the damage from the prior two-week slide. The entire peer group moved higher too — CLSK led at +27.5%, CIFR added 20.4%, HUT gained 17.0%, and RIOT climbed 12.5% — so a broad crypto-mining and AI infrastructure bid is clearly underway. But IREN's move is running ahead of even the fastest peers, which points to something stock-specific amplifying the sector tailwind.
The most likely amplifier is short covering. Short interest is 23.4% of free float — 66.2 million shares — a position that has barely budged week-on-week (up just 1.8%) despite the stock's move. That relative stickiness against a 25% rally is notable; covering against this kind of momentum is painful. Availability has eased slightly to 43%, having been as tight as 21.5% just two weeks ago when the borrow market was near its most stressed. Cost to borrow remains low at 0.66% — up roughly 17% on the week but still far from punishing in absolute terms. The short score is 67.5 and has barely moved all month, sitting in the 7th percentile of its universe. The data suggest the short position remains large and intact, which means there is a meaningful pool of trapped bears if the stock continues to climb.
Options positioning has turned sharply more defensive — and that's now the most interesting signal in the data. The put/call ratio hit 0.80 on Tuesday, more than three standard deviations above its 20-day average of 0.64. That's the highest PCR reading in a year, approaching the 52-week peak of 0.84. A week ago the ratio was a relatively relaxed 0.67. The surge in put demand against a rallying stock is unusual — it reads less like capitulation buying and more like investors hedging a position that has moved fast and far. Either existing longs are buying downside protection into the run, or new money is entering cautiously and paying for insurance on the way in.
The Street is broadly bullish but divided on magnitude. B. Riley raised its target to $88 on May 27, maintaining Buy. Macquarie lifted to $90 two weeks ago with Outperform. HC Wainwright and BTIG both raised targets to $85 and $80 respectively after the May 7 earnings print. The bull case centres on the $2.3B annualised revenue run-rate already under contract, the Oklahoma 1.6GW campus, and the AI cloud services ramp. The dissenting voice is JP Morgan, which maintained Underweight while nudging its target up to $46 — now 23% below the current price. The consensus mean target of $75.34 is also below the current price, which is a notable data point: the stock has traded through most analyst targets on this week's move. The price-to-book multiple has expanded sharply, rising 8.3 points over 30 days to 11.2x, reflecting how quickly sentiment has shifted in the stock's favour.
Institutional flows tell a mixed story. BlackRock added 3.8 million shares as of April 30 and is now a 1.25% holder. UBS Asset Management added 1.6 million in the same period. On the other side, Morgan Stanley trimmed by 3.6 million shares and D.E. Shaw cut by 5.3 million. The net effect is a rotation rather than a directional sweep — active managers pruning while passive-adjacent flows accumulate. Insider data is stale (last trades in September 2025, when the co-CEOs sold at $33), so it adds no current read.
With the stock now trading above its analyst consensus target, the tension worth watching into August earnings is whether the short position — still at 23% of float — begins to unwind in earnest, and whether the unusually elevated put/call ratio reflects transient hedging or a more durable shift in how options traders are reading the risk ahead.
See the live data behind this article on ORTEX.
Open IREN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
